topoisomerase I inhibitors

Preferred Label : topoisomerase I inhibitors;

MeSH definition : Compounds that inhibit the activity of DNA TOPOISOMERASE I.;

MeSH synonym : inhibitors, topoisomerase I; topoisomerase 1 inhibitors; inhibitors, topoisomerase 1; DNA topoisomerase I inhibitors; DNA type 1 topoisomerase inhibitors; Topoisomerase 1 Inhibitor; 1 Inhibitor, Topoisomerase; Inhibitor, Topoisomerase 1; Topoisomerase I Inhibitor; I Inhibitor, Topoisomerase; Inhibitor, Topoisomerase I; DNA Topoisomerase I Inhibitor; DNA Type 1 Topoisomerase Inhibitor;

MeSH Hyperonym : III Inhibitors, Topoisomerase; Inhibitors, Topoisomerase III; Topoisomerase III Inhibitor; III Inhibitor, Topoisomerase; Inhibitor, Topoisomerase III; DNA Topoisomerase III Inhibitor; DNA Topoisomerase III Inhibitors; Topoisomerase 3 Inhibitor; 3 Inhibitor, Topoisomerase; Inhibitor, Topoisomerase 3; Topoisomerase 3 Inhibitors; 3 Inhibitors, Topoisomerase; Inhibitors, Topoisomerase 3; DNA Type III Topoisomerase Inhibitors; DNA Type III Topoisomerase Inhibitor;

Is substance : O;

action pharmacologique : O;

Details

Origin ID

D059004;

UMLS CUI

C0594374;

ATC code(s)
- Topoisomerase 1 (TOP1) inhibitors [ATC Code]
Allowable qualifiers
- administration and dosage [MeSH Qualifier]
- adverse effects [MeSH Qualifier]
- analysis [MeSH Qualifier]
- blood [MeSH Qualifier]
- cerebrospinal fluid [MeSH Qualifier]
- chemical synthesis [MeSH Qualifier]
- chemistry [MeSH Qualifier]
- classification [MeSH Qualifier]
- contraindications [MeSH Qualifier]
- economics [MeSH Qualifier]
- history [MeSH Qualifier]
- immunology [MeSH Qualifier]
- isolation and purification [MeSH Qualifier]
- metabolism [MeSH Qualifier]
- pharmacokinetics [MeSH Qualifier]
- pharmacology [MeSH Qualifier]
- poisoning [MeSH Qualifier]
- radiation effects [MeSH Qualifier]
- standards [MeSH Qualifier]
- supply and distribution [MeSH Qualifier]
- therapeutic use [MeSH Qualifier]
- toxicity [MeSH Qualifier]
- urine [MeSH Qualifier]
Automatic exact mappings (from CISMeF team)
- Topoisomerase 1 (TOP1) inhibitors [ATC Code]
- Topoisomerase-II Inhibitor [NCIt concept]
CISMeF manual mappings
- Product containing topoisomerase inhibitor (product) [SNOMED CT concept]
Currated CISMeF NLP mapping
- Topoisomerase-I Inhibitor [NCIt concept]
Indexing information
- 2-hydroxy-4,5-methylenedioxypropiophenone [MeSH Supplementary Concept]
- 3,5-dihydroxybenzyl alcohol [MeSH Supplementary Concept]
- 4,4'-(3H,3'H-5,5'-bibenzimidazole-2,2'-diyl)dianiline [MeSH Supplementary Concept]
- 7-cyclohexylfluorocamptothecin [MeSH Supplementary Concept]
- 7-phenyl-6H-(1,2,5)oxadiazolo(3,4-e)indole 3-oxide [MeSH Supplementary Concept]
- 9-methoxy-6-(piperazin-1-yl)-11H-indeno(1,2-c)quinoline-11-one O-3-(dimethylamino)propyl oxime [MeSH Supplementary Concept]
- anziaic acid [MeSH Supplementary Concept]
- cyclohexyl(2-phenylquinazolin-4-yl)amine [MeSH Supplementary Concept]
- dehydropachymic acid [MeSH Supplementary Concept]
- etirinotecan pegol [MeSH Supplementary Concept]
- saracoside [MeSH Supplementary Concept]
MeSH Descriptor(s) used for indexing
- DNA topoisomerases, type I [MeSH Descriptor]
Record concept(s)
- Topoisomerase III Inhibitors [MeSH concept]
- topoisomerase I inhibitors [MeSH concept]
Semantic type(s)
- Pharmacologic Substance [UMLS semantic type]
Substance(s)
- 1-cyclopropyl-6-hydroxy-8-methyl-4-oxo-7-(1,2,3,4-tetrahydro-2-isoquinolyl)-1,4-dihydroquinoline-3-carboxylic acid [MeSH Supplementary Concept]
- 10,11-methylenedioxy-20-camptothecin [MeSH Supplementary Concept]
- 2,3-dihydro-9-ethyl-5-fluoro-9-hydroxy-4-methyl-1H,12H-benzo(de)pyrano(3',4'-6,7)indolizino(1,2-b)quinoline-10,13(9H,15H)-dione [MeSH Supplementary Concept]
- 2,3-dimethoxy-8,9-methylenedioxy-11H-indeno(1,2-c)isoquinoline [MeSH Supplementary Concept]
- 2,5-bis(4-hydroxy-3-methoxybenzylidene)cyclopentanone [MeSH Supplementary Concept]
- 2-acyl-5,8-dimethoxy-1,4-naphthoquinone [MeSH Supplementary Concept]
- 3,9-dibromo-12-(4-O-methylglucopyranosyl)-6,7.12,13-tetrahydroindolo(2,3-a)pyrrolo(3,4-c)carbazole-5,7-dione [MeSH Supplementary Concept]
- 3-O-(N-(phenylsulfonyl)carbamoyl-17beta-N-(phenylsulfonyl)amide)betulinic acid [MeSH Supplementary Concept]
- 3-O-(glucopyranosyl-1-4-arabinopyranosyl)hederagenin [MeSH Supplementary Concept]
- 3-O-alpha-L-arabinopyranosyl-oleanolic acid [MeSH Supplementary Concept]
- 4,11-dimethoxynaphtho(2,3-f)indole-5,10-dione [MeSH Supplementary Concept]
- 4-methoxybenzo(a)phenazine-11-carboxylic acid (2-(dimethylamino)-1-methylethyl)amide [MeSH Supplementary Concept]
- 5-ethyl-9,10-difluoro-1,4,5,13-tetrahydro-5-hydroxy-3H,15H-oxepino(3',4'-6,7)indolizino(1,2-b)quinoline-3,15-dione [MeSH Supplementary Concept]
- 5-phenyl-2-(2'-(benzimidazol-5''-yl)benzimidazol-5'-yl)benzimidazole [MeSH Supplementary Concept]
- 6-((2-(dimethylamino)ethyl)amino)-3-hydroxy-7H-indeno(2,1-c)quinolin-7-one [MeSH Supplementary Concept]
- 6-(3-(2-hydroxyethyl)amino-1-propyl)-5,6-dihydro-2,3-dimethoxy-8,9-methylenedioxy-5,11-dioxo-11H-indeno(1,2-)isoquinoline [MeSH Supplementary Concept]
- 6-acyl-5,8-dimethoxy-1,4-naphthoquinone [MeSH Supplementary Concept]
- 7-tert-butyldimethylsilyl-10-hydroxyhomocamptothecin [MeSH Supplementary Concept]
- ACH 702 [MeSH Supplementary Concept]
- BE 13793C [MeSH Supplementary Concept]
- BM 2419-1 [MeSH Supplementary Concept]
- BM 2419-2 [MeSH Supplementary Concept]
- CPUY013 compound [MeSH Supplementary Concept]
- Cl-DACA [MeSH Supplementary Concept]
- Irinotecan [MeSH Descriptor]
- LMP517 [MeSH Supplementary Concept]
- N,N-bis(3-(5-bromoacridine-4-carboxamido)propyl)methylamine [MeSH Supplementary Concept]
- N,N-bis(3-(5-methylacridine-4-carboxamido)propyl)methylamine [MeSH Supplementary Concept]
- NU-ICRF 500 [MeSH Supplementary Concept]
- S 38809 [MeSH Supplementary Concept]
- TAN 1496 A [MeSH Supplementary Concept]
- TAN 1496 C [MeSH Supplementary Concept]
- TAN 1496 E [MeSH Supplementary Concept]
- TAN 1518 A [MeSH Supplementary Concept]
- TAN 1518 B [MeSH Supplementary Concept]
- belotecan [MeSH Supplementary Concept]
- bis-1,3-((5,6-dihydro-5,11-diketo-11H-indeno(1,2-c)isoquinoline)-6-propylamino)propane [MeSH Supplementary Concept]
- camptothecin [MeSH Descriptor]
- cauloside A [MeSH Supplementary Concept]
- chebulagic acid [MeSH Supplementary Concept]
- demethylzeylasterone [MeSH Supplementary Concept]
- dicentrinone [MeSH Supplementary Concept]
- ethoxidine [MeSH Supplementary Concept]
- exatecan [MeSH Supplementary Concept]
- indolocarbazole derivative R-6 [MeSH Supplementary Concept]
- isocamptothecin A [MeSH Supplementary Concept]
- isocamptothecin B [MeSH Supplementary Concept]
- kalihinol F [MeSH Supplementary Concept]
- leptosin C [MeSH Supplementary Concept]
- leptosin F [MeSH Supplementary Concept]
- lysyl-cysteinyl-cysteinyl-arginyl-cysteinyl-lysine [MeSH Supplementary Concept]
- norindenoisoquinoline [MeSH Supplementary Concept]
- rosettacin [MeSH Supplementary Concept]
- rubitecan [MeSH Supplementary Concept]
- topopyrone A [MeSH Supplementary Concept]
- topopyrone B [MeSH Supplementary Concept]
- topopyrone C [MeSH Supplementary Concept]
- topopyrone D [MeSH Supplementary Concept]
- topostatin [MeSH Supplementary Concept]
- topostin A1 [MeSH Supplementary Concept]
- topostin A2 [MeSH Supplementary Concept]
- topostin B [MeSH Supplementary Concept]
- topotecan [MeSH Descriptor]
- tryptophyl-tyrosyl-cysteinyl-arginyl-cysteinyl-lysine [MeSH Supplementary Concept]
UMLS correspondences (same concept)
- Topoisomerase-I Inhibitor [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients